Onyx Bio builds a longitudinal, data-driven model of human immune response. It collects multi-omics data from the same participants over time—single-cell transcriptomics with T- and B-cell receptor tracking, proteomics of about 1,000 plasma proteins, metabolomics, and genomics—linked to clinical events like infection, vaccination, or treatment changes. All samples are processed in their own Berkeley lab, and participants include healthy adults and people with autoimmune disease who participate in discovery. The goal is to accelerate medicine development by improving understanding of immune biology and how treatments affect it through detailed, time-resolved data.
Company Size
1-10
Company Stage
Seed
Total Funding
$8M
Headquarters
N/A
Founded
2024
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?